Scientist 2
Lexeo Therapeutics
Scientist 2
Lexeo Therapeutics
Gene therapy for cardiac, neurological diseases
Salary Range: 99680 to 138500 (Currency: USD) (Pay period: per-year-salary)
Role Summary
This Scientist II will independently design, execute, and analyze research studies and will drive one or more analytical development projects for AAV-based gene therapy programs. The role provides technical leadership in the development, optimization, qualification, validation, and transfer of analytical assays, including cell-based potency and molecular methods such as qPCR and ddPCR. The Scientist II will apply broad scientific knowledge and novel approaches to establish AAV mechanisms of action in cellular systems, resolve moderately complex technical issues, and support GMP manufacturing, material release, and regulatory submissions in collaboration with groups across CMC, Quality, QC, and external partners.
The ideal candidate is highly collaborative, detail-oriented, able to manage multiple priorities, and effective in a fast-paced environment. The Scientist II is expected to exercise sound scientific judgment, communicate complex technical issues clearly, build alignment across functions, and serve as a technical resource to colleagues. This is a highly visible and impactful role in our CMC organization.
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Gene therapy for cardiac, neurological diseases
Lexeo Therapeutics develops gene therapies for genetic cardiac and neurological diseases. It advances therapies by conducting research, running clinical trials, and pursuing commercialization through partnerships and grants. It differentiates itself with a strong academic foundation and collaboration with Weill Cornell’s Department of Genetic Medicine, while focusing on end-to-end development from discovery to trials. Its goal is to bring genetic medicines to patients with unmet medical needs through partnerships, clinical trials, and eventual market availability.
Explore more opportunities at Lexeo Therapeutics